São Paulo, August 20, 2025 – Eurofarma, a Brazilian multinational present in 24 countries and covering 100% of Latin America, has once again been recognized as one of the most innovative pharmaceutical and life sciences industries in Brazil, according to the 2025 Valor Inovação Award. This is the fifth consecutive year that the company has ranked among the most innovative firms in the country, reaffirming its commitment to transforming healthcare through science, technology, and an entrepreneurial spirit.

In 2024, Eurofarma reached the first position in the ranking, the result of a consistent strategy that integrates product innovation and digital innovation into a robust platform of healthcare solutions. Investments in innovation exceeded R$ 800 million for the year, representing a 25% growth compared to the previous year.

Currently, the company's pipeline includes more than 400 projects, ranging from generics to incremental and radical innovation. In the radical innovation front, two projects are about to enter phase 1 of clinical studies, led by a highly qualified team. In the digital field, Eurofarma continues to advance with initiatives in artificial intelligence, digital therapeutics, and partnerships with startups through the EurON Ventures program.

This recognition reinforces the relevance of Eurofarma's innovation strategy and its role in developing healthcare solutions that keep pace with industry transformations.

About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector, producing and marketing products and services to improve people's quality of life. Focused on shared value generation, it covers key pharmaceutical segments such as prescription drugs, OTC and personal care, generics, hospital, oncology, and animal health, in addition to providing third-party manufacturing services. With broad coverage across therapeutic classes, the portfolio comprises over 4,000 SKUs, serving major medical specialties. A leader in medical prescriptions in Brazil, Eurofarma is present in 24 countries, with 100% coverage in Latin America and operations in the USA and Africa. It has 13,300 employees and 11 manufacturing plants.

Press Information
G&A Relações Públicas
e-mail: imprensaeurofarma@gaspar.com.br
Iza França - +55 11 97644-4496 
Guilherme Gaspar - +55 11 98285-6000